Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

Company Overview

Bright Minds Biosciences Inc., trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders. Its second program, BMB-103, is in preclinical development targeting neuroinflammation and neuronal survival pathways relevant to Alzheimer’s disease. Bright Minds Biosciences operates research facilities in Vancouver and Montreal, collaborating with academic institutions and industry partners to advance its pipeline through both early-stage and later-stage clinical studies.

Founded in 2020, Bright Minds completed its initial public listing to support ongoing research and development activities. The company’s leadership team includes experienced researchers, medicinal chemists and clinical development experts committed to translating cutting-edge neuroscience into scalable therapies. By focusing on small-molecule alternatives to traditional biologics, Bright Minds Biosciences seeks to offer patients oral treatments with favorable safety profiles and broad commercial applicability.

Key Stats

• Today's Range: $88.00 to $90.08
• 50-Day Range: $68.45 to $90.79
• 52-Week Range: $23.17 to $123.75
• Volume: 79,934 shs
• Average Volume: 172,686 shs
• Market Capitalization: $855.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $128.60
• Consensus Rating: Moderate Buy

Bright Minds Biosciences Stock Analysis - MarketRank™

Bright Minds Biosciences scored higher than 69% of companies evaluated by MarketBeat, and ranked 215th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bright Minds Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Bright Minds Biosciences has a consensus price target of $128.60, representing about 44.1% upside from its current price of $89.24.

Amount of Analyst Coverage

Bright Minds Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($5.30) to ($8.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bright Minds Biosciences is -46.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bright Minds Biosciences is -46.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bright Minds Biosciences has a P/B Ratio of 10.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.62% of the float of Bright Minds Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Bright Minds Biosciences has a short interest ratio ("days to cover") of 3.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bright Minds Biosciences has recently decreased by 7.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bright Minds Biosciences does not currently pay a dividend.

Dividend Growth

Bright Minds Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.85

News Sentiment

Bright Minds Biosciences has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Bright Minds Biosciences this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bright Minds Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,785,124.00 in company stock.

Percentage Held by Insiders

42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DRUG Stock Analysis - Frequently Asked Questions

How have DRUG shares performed this year?

Bright Minds Biosciences' stock was trading at $78.04 at the beginning of 2026. Since then, DRUG stock has increased by 14.3% and is now trading at $89.2350.

How were Bright Minds Biosciences' earnings last quarter?

Bright Minds Biosciences Inc. (NASDAQ:DRUG) announced its quarterly earnings results on Thursday, February, 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.98) by $0.28.

When did Bright Minds Biosciences' stock split?

Bright Minds Biosciences shares reverse split on Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Who are Bright Minds Biosciences' major shareholders?

Bright Minds Biosciences' top institutional investors include Bank of New York Mellon Corp (0.14%), AdvisorShares Investments LLC (0.13%) and Strs Ohio (0.03%).
View institutional ownership trends.

How do I buy shares of Bright Minds Biosciences?

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bright Minds Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 2/12/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/15/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRUG
• CIK: 1827401
• Web: brightmindsbio.com
• Phone: 64-7407-2515
• Fax: N/A
• Employees: N/A
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Bright Minds Biosciences: $128.60
• High Price Target: $147.00
• Low Price Target: $80.00
• Potential Upside/Downside: +44.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.74 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -28.62%
• Return on Assets: -28.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 57.38
• Quick Ratio: 57.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.33 per share
• Price / Book: 10.71

Miscellaneous

• Outstanding Shares: 9,732,000
• Free Float: 5,580,000
• Market Cap: $868.44 million
• Optionable: Not Optionable
• Beta: -5.35